Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics
MWN-AI** Summary
Codexis, Inc. (NASDAQ: CDXS), a frontrunner in enzymatic solutions for manufacturing therapeutics, has announced a significant partnership with Axolabs, an established Contract Research Development and Manufacturing Organization (CRDMO) that is part of LGC Group. The collaboration centers around the evaluation of Codexis’ ECO Synthesis® Manufacturing Platform, specifically designed for the production of oligonucleotide therapeutics.
The agreement gives Axolabs the opportunity to assess Codexis’ innovative enzymatic synthesis capabilities, which are aimed at enhancing the efficiency and scalability of RNA manufacturing. Codexis' President and CEO, Alison Moore, emphasized the importance of expanding the platform's reach through collaborations with top-tier CDMOs like Axolabs. This partnership not only bolsters Codexis' position in the biopharmaceutical industry but also opens the door for future licensing discussions and broader adoption of their manufacturing platform.
Kathleen Campau, Senior Director of Operations at Axolabs, highlighted the transformative potential of this technology in advancing sustainable and cost-effective production methods for therapeutic oligonucleotides. She noted that this collaboration is a natural extension of Axolabs’ commitment to pushing the boundaries of nucleic acid therapeutics and aligns perfectly with their mission.
Both companies are dedicated to enhancing access to high-quality oligonucleotide-based medicines on a global scale. Codexis is recognized for its proprietary CodeEvolver® technology, which allows the development of high-performance enzymes, enabling improved yields and reduced resource consumption in manufacturing processes. Through this partnership, Codexis and Axolabs aim to make strides in the field of RNA therapeutics and further provide innovative solutions to address pressing healthcare needs.
MWN-AI** Analysis
Codexis, Inc. (NASDAQ: CDXS) has taken a significant strategic step by entering an evaluation agreement with Axolabs, a notable player in the Contract Research Development and Manufacturing (CRDMO) space. This partnership is positioned to enhance Codexis' ECO Synthesis® Manufacturing Platform, particularly for oligonucleotide therapeutics. Investors should closely monitor this development as it has the potential to influence the growth trajectory of Codexis in the emerging field of RNA therapeutics.
The ECO Synthesis Manufacturing Platform leverages innovative enzymatic synthesis technology, which not only improves production efficiencies but also promises sustainability in manufacturing — a crucial factor as global demand for environmentally responsible processes rises. With Axolabs' expertise in oligonucleotide drug production, the partnership has the potential to catalyze the commercialization of this platform, leading to a possible uptick in revenue for Codexis as it scales operations.
Market analysts point out that the oligonucleotide therapeutics space is forecasted to grow significantly, thus a well-timed collaboration could position Codexis favorably within this booming market. The evaluation agreement serves as a precursor to potential licensing discussions that could further expand Codexis’ market presence.
From a financial perspective, investors should consider the potential upside of Codexis shares, especially if Axolabs successfully validates the ECO Synthesis platform. As Codexis focuses on scalability and cost efficiency, these developments could lead to stronger sales projections and broader investor interest.
In conclusion, Codexis’ agreement with Axolabs presents a compelling opportunity that underscores the company's innovative approach and commitment to pioneering new manufacturing solutions. Investors may want to initiate a position in CDXS to capitalize on this growth potential as the partnership unfolds.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization (CRDMO), today announced that they have entered into an agreement under which Axolabs will evaluate Codexis' ECO Synthesis Manufacturing Platform.
This partnership provides Axolabs access to an innovative, scalable RNA manufacturing solution powered by enzymatic synthesis. The Agreement paves the way for future licensing discussions and potentially broader adoption of the platform.
"Part of our mission is to expand the reach of our ECO Synthesis Manufacturing Platform through collaborations with best-in-class CDMOs," said Alison Moore, President & CEO of Codexis. "Axolabs is an industry-leading CRDMO, and we are delighted to enter into this partnership with them to enable more efficient manufacturing of oligonucleotide therapeutics that address large markets."
Kathleen Campau, Senior Director of Operations for Axolabs said: "This technology has the potential to be pivotal to how therapeutic oligonucleotides are manufactured at scale in the future, enabling more sustainable and cost-effective production. At Axolabs, we are committed to advancing the science behind therapeutic oligonucleotides, and this partnership builds on our long-standing legacy of technology leadership in the field".
The Codexis and Axolabs collaboration reinforces both companies' commitment to excellence and expanding access to high-quality oligonucleotide-based medicines globally.
About Codexis, Inc.
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis Manufacturing Platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com
About Axolabs
Axolabs is at the frontier of nucleic acid therapeutics, advancing the design, development, and production of life-changing RNA-based drugs. From early discovery to GMP manufacturing, we offer an end-to-end platform that helps biotech and pharma partners bring innovative therapies to patients faster.
Our global presence includes state-of-the-art sites in Kulmbach, Berlin, and Petaluma, with each site specialising in a specific phase of your drug development journey.
Axolabs is part of LGC Group. For more information, please visit https://www.axolabs.com
SOURCE Codexis
FAQ**
How will the partnership between Codexis Inc. (NASDAQ: CDXS) and Axolabs enhance the scalability and efficiency of RNA manufacturing in the oligonucleotide therapeutics market?
In what ways could Codexis Inc. (CDXS) leverage its ECO Synthesis Manufacturing Platform to drive cost reductions and sustainability throughout the oligonucleotide production process?
What are the anticipated benefits for Codexis Inc. (CDXS) in terms of future licensing opportunities as a result of this evaluation agreement with Axolabs?
Can you provide insights on how Axolabs intends to incorporate Codexis Inc. (CDXS) enzymatic solutions into its existing workflow for developing therapeutic oligonucleotides?
**MWN-AI FAQ is based on asking OpenAI questions about Codexis Inc. (NASDAQ: CDXS).
NASDAQ: CDXS
CDXS Trading
2.47% G/L:
$1.245 Last:
492,064 Volume:
$1.23 Open:
